The Altman Companies
Purchase-Price Allocation
Goodwill
$31.2M
Assets Acquired
$50.1M
Liabilities Assumed
$53.5M
Pro-Forma Combined Entity
Revenue
$415.4M
Net Income
−$34.3M
BBX Capital, Inc. — Key Metrics
1 years of history · ending 2024-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-5
Book Value Per Share
$18
Free Cash Flow Per Share
$-3
Cash Per Share
$6
Revenue Per Share
$22
OCF Per Share
$-2
Return on Equity
-22.9%
Return on Assets
-10.0%
Return on Invested Capital
-17.7%
Asset Turnover
0.48
Days Sales Outstanding
19.11
SBC / Revenue
1.9%
Capex / Revenue
2.3%
Net Current Asset Value
$-294M
Invested Capital
$246M
OCF / Net Income
0.53
FCF / Net Income
0.64
Accruals Ratio (Sloan)
-5.0%
Net Debt
$-88M
Net Debt / EBITDA
1.72
Interest Coverage
-19.89
Cash Coverage
-10.83
Capex Coverage
-4.71
Tangible Common Equity
$172M
TCE / Total Assets
28.5%
Goodwill / Total Assets
8.2%
NOPAT
$-49M
Cash ROIC
-14.8%
Capex / D&A
0.63
Reinvestment Rate
6.8%
Total Payout Ratio
-6.8%
Asset Growth vs Revenue Growth
12.9%
Revenue 5Y CAGR
8.6%
Book Value 5Y CAGR
6.1%
Stock Price (FY-end)
$6
Market Cap
$77M
P/E Ratio
—
P/S Ratio
0.25
P/B Ratio
0.31
P/TB Ratio
0.45
P/OCF Ratio
—
P/FCF Ratio
—
Enterprise Value
$-11M
EV / EBITDA
—
EV / Sales
-0.04
EV / FCF
—
FCF Yield
-53.8%
Shareholder Yield
-1.8%
Buyback Yield
5.7%
Capex Yield
9.4%
Operating Leverage
—
Graham Number
—
Shares Variation (YoY)
-5.1%
Beta (5Y)
0.20
Cost of Equity
5.5%
52W High
$7
52W Low
$6
Trailing Return 1Y
-19.6%
F-Score (Piotroski)
2.00
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Stock Price on Earnings Dates
BBX Capital, Inc. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | — | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | 4.16% | 5.89% | 0.49% | -2.18% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | — | — | 0.48% | -0.85% | 0.31% | -0.21% |
| SBC (Nondeductible) | — | — | 0.00% | 3.39% | -10.31% | -3.97% |
| Valuation Allowance Change | — | — | 0.66% | 4.79% | -7.84% | -30.64% |
| Effective Tax Rate | -29.00% | 19.00% | 26.74% | 35.40% | 9.48% | -13.50% |
Cash vs Accrual
| Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $8.3M | −$11.2M | $17.2M | $15.1M | −$2.1M | $7.7M |
| Income Taxes Paid (Cash) | — | — | — | — | — | — |
BBX Capital, Inc. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
The Altman Companies Llc
Pro-Forma Combined Entity
Net Income
+$22.6M